Patents by Inventor Ramon A. Burns, Jr.
Ramon A. Burns, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5550188Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.Type: GrantFiled: June 7, 1995Date of Patent: August 27, 1996Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5543441Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: April 24, 1995Date of Patent: August 6, 1996Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5523348Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: August 18, 1994Date of Patent: June 4, 1996Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5446091Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.Type: GrantFiled: January 5, 1995Date of Patent: August 29, 1995Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5413791Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.Type: GrantFiled: February 17, 1994Date of Patent: May 9, 1995Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5376375Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: January 5, 1994Date of Patent: December 27, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5328955Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.Type: GrantFiled: July 30, 1992Date of Patent: July 12, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5324775Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding biologically inactive, natural, biocompatible polymer to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide biocompatible conjugates. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object. The dehydrated, solid object can be ground into particles which can be suspended in a non-aqueous fluid such as an oil and injected into a living (preferably human) being for the purpose of providing soft tissue augmentation.Type: GrantFiled: July 2, 1992Date of Patent: June 28, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5306500Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: August 23, 1993Date of Patent: April 26, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5304595Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: December 30, 1992Date of Patent: April 19, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5264214Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: August 14, 1992Date of Patent: November 23, 1993Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5162430Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: November 14, 1989Date of Patent: November 10, 1992Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5028430Abstract: An implantable polymeric delivery system for the controlled and continuous administration of an LHRH agonist which comprises a silicone elastomer matrix in which is dispersed about 30 to about 42 weight percent of water-soluble particulate phase containing an LHRH analog or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 8, 1987Date of Patent: July 2, 1991Assignee: Syntex (U.S.A.) Inc.Inventors: Lynda M. Sanders, Ramon A. Burns, Jr.